Sobi to Host Call & Webcast Detailing NASP and Uncontrolled Gout Progress
Stockholm, Sweden – Sobi, a global biopharmaceutical company focused on rare diseases, today announced it will host a call and webcast to discuss recent advancements in itS North American Specialty products (NASP) portfolio and ongoing efforts in uncontrolled gout.The event is scheduled for May 9, 2024, at 8:00 AM Eastern Time.
This presentation arrives as Sobi navigates a critical period for its NASP business and seeks to address the significant unmet needs of patients suffering from debilitating gout. With approximately 1,900 employees worldwide and 2024 revenue reaching SEK 26 billion, Sobi’s progress in these areas is closely watched by investors and the medical community alike. The call will provide insights into the company’s strategic direction and potential impact on its Nasdaq Stockholm-listed share (STO:SOBI).
Attendees can access the live webcast and accompanying presentation materials via the Sobi Investor Relations website: https://www.sobi.com/en/ir-contacts. A replay of the webcast will be available shortly after the event concludes.gerard Tobin, Head of Investor Relations, will lead the presentation and be available to address investor questions. Further details regarding Investor Relations contacts can be found at https://www.sobi.com/en/ir-contacts, while media inquiries should be directed through the Sobi Media contacts page: https://www.sobi.com/en/media.
More data about Sobi and its commitment to rare disease innovation can be found at https://www.sobi.com/en and on LinkedIn: https://www.linkedin.com/company/sobi/.
